Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN   US09061G1013

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
92.9(c) 91.52(c) 87.23(c) 86.06(c) 87.21(c) Last
1 458 903 830 568 2 018 934 1 508 821 1 575 123 Volume
+1.64% -1.49% -4.69% -1.34% +1.34% Change
More quotes
Company
BioMarin Pharmaceutical, Inc. develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.The company operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's product portfolio is comprised of... 
Sector
Pharmaceuticals
Calendar
02/19Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 708 M
EBIT 2014 -121 M
Net income 2014 -153 M
Debt 2014 218 M
Yield 2014 -
Sales 2015 874 M
EBIT 2015 -256 M
Net income 2015 -307 M
Debt 2015 429 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 18,5x
EV / Sales 2015 15,2x
Capitalization 12 860 M
More Financials
Latest news on BIOMARIN PHARMACEUTICAL IN
7d ago BIOMARIN PHARMACEUTICAL : Brazil approves BioMarin's Vimizim to treat morquio A ..
12/10 BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of M..
12/10 FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250..
12/09 BIOMARIN PHARMACEUTICAL : Vimizim gets approval in Australia to treat Morquio A ..
12/09 BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst a..
12/07 BIOMARIN PHARMACEUTICAL : VIMIZIM(R) (elosulfase alfa) Approved in Australia for..
12/04 BIOMARIN PHARMACEUTICAL : CureDuchenne Media Statement Regarding BioMarin's and ..
12/04 BIOMARIN PHARMACEUTICAL : RNA INVESTOR ALERT: Levi & Korsinsky, LLP Announces In..
More news
Sector news
53m agoDJAstraZeneca's Lynparza Approved in EU for Ovarian Cancer Patients
1h ago ASTRAZENECA : Gets Marketing Approval For Lynparza Cancer Treatment
1h ago ASTRAZENECA : Lynparza™approved in the European Union as first-in-class tr..
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF